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Abstract: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders 
caused by deficiency of the lysosomal enzymes essential for catabolism of glycosaminoglycans 
(GAGs). Accumulation of undegraded GAGs results in dysfunction of multiple organs, 
resulting in distinct clinical manifestations. A range of methods have been developed to 
measure specific GAGs in various human samples to investigate diagnosis, prognosis, 
pathogenesis, GAG interaction with other molecules, and monitoring therapeutic efficacy. We 
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established ELISA, liquid chromatography tandem mass spectrometry (LC-MS/MS), and an 
automated high-throughput mass spectrometry (HT-MS/MS) system (RapidFire) to identify 
epitopes (ELISA) or disaccharides (MS/MS) derived from different GAGs (dermatan 
sulfate, heparan sulfate, keratan sulfate, and/or chondroitin sulfate). These methods have a 
high sensitivity and specificity in GAG analysis, applicable to the analysis of blood, urine, 
tissues, and cells. ELISA is feasible, sensitive, and reproducible with the standard equipment. 
HT-MS/MS yields higher throughput than conventional LC-MS/MS-based methods while 
the HT-MS/MS system does not have a chromatographic step and cannot distinguish 
GAGs with identical molecular weights, leading to a limitation of measurements for some 
specific GAGs. Here we review the advantages and disadvantages of these methods for 
measuring GAG levels in biological specimens. We also describe an unexpected secondary 
elevation of keratan sulfate in patients with MPS that is an indirect consequence of 
disruption of catabolism of other GAGs. 
Keywords: mucopolysaccharidoses; ELISA; tandem mass spectrometry; glycosaminoglycan; 
chondroitin sulfate; dermatan sulfate; heparan sulfate; keratan sulfate 
 
1. Introduction 
The mucopolysaccharidoses (MPSs) are a group of lysosomal storage diseases (LSDs) caused by 
deficiency of the lysosomal enzymes required to degrade glycosaminoglycans (GAGs) such as dermatan 
sulfate (DS), heparan sulfate (HS), keratan sulfate (KS), chondroitin sulfate (CS), and hyaluronan [1,2]. 
Each type of MPS causes accumulation of particular GAG (s) (Table 1). In MPSs, the undegraded 
GAGs are stored in lysosomes and extracellular matrix (ECM) of a variety of tissues, secreted into the 
bloodstream, and excreted in the urine. Accumulated GAGs lead to cell dysfunction and abnormal structure 
of ECM, causing progressive damage of multiple tissues including CNS, lung, heart, liver, spleen, 
kidney, joint, and bone. There are 11 known enzyme deficiencies, resulting in seven distinct forms of 
MPS. The collective incidence is more than 1 in 25,000 live births. Most patients with MPS are 
asymptomatic as newborns, with subsequent onset of clinical signs and symptoms that include inguinal 
or umbilical hernia, abnormal development of bones, short stature, coarse hair, hepatosplenomegaly, and 
mental retardation during infancy or childhood. In most patients, these clinical manifestations progress 
over several years. While the symptoms and severity of MPS vary with each patient and its subtype of 
MPS, the average life span in most patients is one to two decades if untreated.  
Enzyme replacement therapy (ERT) [3–5], hematopoietic stem cell transplantation (HSCT) [6–9], 
substrate reduction therapy (SRT) [10,11], gene therapy [12,13], and anti-inflammatory drugs [14,15] 
are in clinical use or being investigated under clinical trials for patients with some types of MPS. 
Initiating these treatments at birth or during early stages provides most benefits in the clinical 
improvement of the disease. Therefore, successful treatment of these disorders depends on early 
diagnosis. Identification of disease biomarkers is of inevitable importance in diagnosis, clinical 
severity and its prognosis, pathogenesis, and monitoring for therapies. 
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Table 1. Correlation between mucopolysaccharidoses and GAG (s). 







MPS I (Hurler) α-L-Iduronidase (IDUA) AR 4p16.3 DS, HS ↑↑↑ 
MPS II (Hunter) Iduronate-2-sulfatase (IDS) XR Xq28 DS, HS ↑↑↑ 
MPS IIIA  
(Sanfillipo A) 
Heparan-N-sulfatase (SGSH) AR 17q25.3 HS ↑ 




AR 17q21 HS ↑ 




AR 8p11-q13 HS ↑ 




AR 12q14 HS NA 
MPS IVA  
(Morquio A) 
Galactose 6-sulfatase,  
N-acetylgalactosamine-6-sulfate 
sufatase (GALNS) 
AR 16q24.3 C6S, KS ↑↑↑ 
MPS IVB  
(Morquio B) 





AR 5q13.3 C4S, DS ↑↑ 
MPS VII (Sly) β-D-Glucuronidase (GUSB) AR 7q21-q22 C4, 6S, 
DS, HS 
↑↑ 
AR: autosomal recessive, XR: X-linked recessive, C4S: chondroitin 4-sulfate, C6S: chondroitin 6-sulfate, 
DS: dermatan sulfate, HS: heparan sulfate, KS: keratan sulfate. 
GAGs consist of CS, DS, HS, KS, and hyaluronan. These GAGs are identified in various tissues 
and cell types, and occupy major components of the extracellular matrix (ECM) and connective 
tissues. GAGs, except hyaluronan, are sulfated polysaccharides comprising of repeating disaccharides; 
uronic acid (or galactose) and hexosamines. Polymeric GAGs are covalently attached through a linkage 
region to core proteins to produce proteoglycans (PGs). PGs are associated with various physiological 
functions such as hydration and swelling pressure to the tissue to absorb compressional forces, regulation 
of collagen fibril formation, modification of the activity of transforming growth factor-β, and the major 
anionic site responsible for the charge selectivity in glomerular filtration. Sulfation patterns in the 
GAG chains play important roles by permitting interactions, normally of the ionic nature, with growth 
factors. The core proteins are not just scaffolds for GAGs, containing the domains that have particular 
biological activities [16]. Many PGs are multifunctional molecules that engage in different specific 
interactions simultaneously.  
Several procedures have been established to measure GAGs. Dye-spectrometric methods including 
dimethylmethylene blue (DMB) [17–22] and alcian blue [23] were developed to measure total urinary 
GAGs. Thin-layer chromatography (TLC) was used for identification of each specific GAG; however, 
these methods are not adapted to blood or tissue extracts without prior protease, nuclease or 
hyaluronidase digestion. Sensitivity and specificity of dye-spectrometric or the TLC method are not 
sufficient to detect all types of MPS, especially MPS IV. HPLC is a sensitive, reproducible, and 
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accurate method to assay each specific GAG but cannot be applied to mass screening because the 
method is complex and time-consuming [24–26]. 
ELISA assays for KS and HS in blood and urine were established, indicating a better resolution 
between normal controls and patients with MPS I, II, III, IVA, and VII, compared with the DMB 
method [27–29]. ELISAs to measure KS, HS, or DS are rapid and reproducible but expensive. Thus, 
establishment of a simple, accurate, reproducible, and cost-effective GAG assay method is urgently 
needed to apply to not only clinical indications but also basic research.  
We have developed a new approach to assay disaccharides derived from CS, DS, HS, and KS in 
blood, urine, and/or dried blood spot (DBS) samples by using liquid chromatography tandem mass 
spectrometry (LC-MS/MS) [30]. The LC-MS/MS method not only shows sensitivity and specificity 
for detecting all subtypes of MPS, but also monitors therapeutic efficacy in MPS patients and animal 
models; however, since LC processing is still time consuming, the main drawback of this method 
could be throughput.  
The use of an automated high-throughput mass spectrometry (HT-MS/MS) system (RapidFire) 
eliminates the chromatographic process, enabling sample-to-sample cycle times to be reduced from 
minutes to seconds, while maintaining the quality and accuracy of standard LC-MS/MS platform. Each 
sample is processed within ten seconds, indicating that a single HT-MS/MS system can analyze over 
one million samples annually. We recently reported that HT-MS/MS could measure HS levels in 
control human blood much faster than LC-MS/MS, while the HS values produced by HT-MS/MS have 
a strong correlation with those by LC-MS/MS [30]. 
During development of highly sensitive ELISA and LC-MS/MS methods, we found that the original 
concept that “each type of MPS elevates specific GAG(s) in biological specimen based upon the catabolic 
pathway of GAG” is not always true [28,29,31]. Patients with MPS IVA and IVB have a deficiency of 
the enzyme that directly involves KS metabolism; N-acetylgalactosamine-6-sulfate sulfatase (GALNS) 
and β-galactosidase (GLB1), respectively. Therefore, elevation of KS in blood and urine of these types 
of MPS would be expected; however, it would not be expected that patients with other types of MPS, 
in which the responsible enzymes do not directly involve the catabolic pathway of KS, have an 
elevation of KS in blood and urine. In some patients with types of MPS that do not directly involve KS 
catabolism, levels of KS were as high as that in patients with a severe form of MPS IVA [28,31,32]. 
The mechanism by which KS is elevated in these types of MPS has not yet been determined. 
In this article, we review GAG assays that use ELISA, LC-MS/MS, and HT-MS/MS methods.  
We also describe a hypothesis to explain the secondary elevation of KS in blood in patients with MPS 
that do not directly involve metabolic pathways of KS. 
2. ELISA 
2.1. Background 
Total urinary GAG, a potential biomarker for MPS, is measured spectrometrically by using  
DMB [17,18,33,34] or Alcian blue [23,35]; however, these methods cannot be applied to blood 
without protease treatment, since protein in the specimen hinders the binding of the dye to the GAG. 
Moreover, the dye itself tends to decompose, leading to a high background and false positive results. In 
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particular, levels of total urinary GAGs in a substantial number of patients with MPS IVA are within 
the normal range, so it is difficult to diagnose this disease based on only urine GAG excretion [18,27,31].  
2.2. Development of Sandwich ELISA Assay 
Since dye-spectrometric methods have a limitation of sensitivity and specificity, direct measurements of 
specific GAGs, KS and HS, have been developed.  
2.2.1. Keratan Sulfate 
The excessive accumulation of KS in cartilage is known to cause severe skeletal dysplasia in MPS 
IVA, and, therefore, appropriate quantitative method to measure KS in the blood of these patients was 
required. In 1988, Thonar et al. [36] developed an inhibition ELISA to measure blood KS level in 
healthy controls, suggesting that blood KS is age-dependent; however, this monoclonal antibody assay 
for KS measurement involves multiple laborious steps, leading to the requirement of improvements in 
methodology. In 2005, we showed that blood KS is unexpectedly elevated in other types of MPS, 
suggesting that blood KS could be used for screening, prognosing, and monitoring not only MPS IV 
but also other types of MPS [28].  
Plasma KS values more than 2SD above the mean of age-matched controls were found in MPS 
patients as follows (Figure 1; left panel); 16 out of 18 (88.8%) for MPS I, 27 out of 28 (96.4%) for 
MPS II, 16 of 20 (80%) for MPS III, 50 of 62 (80.6%) for MPS IV, 3 out of 3 for MPS VI, and 2 out 
of 5 (40%) for MPS VII. Thus, while over 80.0% patients with MPS IV had plasma KS levels more 
than 2SD above the mean of age-matched controls, for all other forms of MPS the proportion was even 
higher (more than 85%), indicating that elevated plasma KS is found in most MPS patients [28].  
In urine, KS levels are not so markedly elevated in non-MPS IV patients. While 96.4% MPS IV 
patients had urine KS levels more than 2SD above the mean of age-matched controls, this value was 
only 22% for other MPS patients [28]. These findings demonstrate that there is a difference of 
magnitude of elevation in blood and urine KS between MPS IV patients and other MPS patients [28]. 
2.2.2. Heparan Sulfate 
In 2005, we established a sandwich ELISA method for HS measurement in MPS patients and 
showed that blood and urine HS levels are elevated in MPS I, II, III, VI, and VII [29].  
HS levels in plasma showed that 18 of 22 (82.6%) attenuated and 65 of 67 (97%) severe patients 
with MPS I, II, III, and VII were more than 2SD above the mean of age-matched controls, indicating 
that severe patients had a higher frequency of elevated plasma HS.  
Plasma HS values more than 2SD above the mean of age-matched controls are obtained as  
follows (Figure 1; right panel); 23 out of 33 (70%) for MPS I (2 of 5 attenuated; 22 of 29 severe), 29 of 
33 (87.8%) for MPS II (8 of 11 attenuated; 21 of 22 severe), 23 of 30 (76.7%) for MPS III  
(23 of 28 severe; 0 of 2 attenuated), and 5 out of 9 (57.1%) for MPS VII patients  
(4 of 7 attenuated; 1 of 2 severe). Nine of 60 (15%) MPS IVA patients (1 of 13 attenuated; 8 out of  
47 severe) had plasma HS values more than 2SD above the mean of age-matched controls. Plasma HS 
values in all five MPS VI patients were more than 2SD above the mean of controls [29]. 
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Figure 1. Plasma KS and HS levels determined by Sandwich ELISA assay. Left panel 
(plasma KS): The KS standards for ELISA calibration and the anti-KS monoclonal 
antibody (5-D-4) were obtained from Seikagaku (Tokyo, Japan). The ELISA procedure 
was described previously [28]. The absorbance was measured at 450 nm using a microplate 
spectrophotometer reference to 650 nm. The KS concentration was determined by applying 
the absorbance of each sample to the calibration curve [28]. Right panel (Plasma HS): All 
reagents described for HS-ELISA were provided from Seikagaku Co (Tokyo, Japan). 
Monoclonal antibodies against HS were used. The ELISA method was essentially the same 
as described for KS assay. The absorbance was measured at 450 nm (reference absorbance 
630 nm) using a microplate spectrophotometer [29].  
Urine HS values in 13 of 27 (48.1%) attenuated patients and 82 of 89 (92.1%) severe with MPS I, 
II, III and VII were more than 2SD above the mean of age-matched controls, indicating a significant 
frequency of elevated urine HS in patients with severe forms of MPS. Twenty-nine of 75 (38.7%) MPS 
IVA patients (3 of 15 attenuated; 26 of 60 severe) had plasma HS values more than 2SD above the 
mean of controls. Three of seven MPS VI patients showed urine HS levels more that 2SD above the 
mean of controls [29].  
Overall, most MPS patients who lacked enzymes required for catabolism of KS or HS had an 
elevation of KS or HS in blood and urine, respectively; however, many of these patients also had a 
secondary elevation of HS or KS despite having normal levels of enzymes requires to digest these 
particular GAGs. Thus, measurement of both KS and HS in blood and urine are likely to provide 
useful biomarkers to assess clinical severity at an early stage, and to monitor therapeutic efficacy for 
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multiple forms of MPS [28,29,37]. A potential mechanism for these secondary elevations is discussed 
later in this review (see Figure 5).  
3. History of GAG Assay by Tandem Mass Spectrometry (MS/MS)  
Initial MS methods for GAG assays were developed to detect heparin oligosaccharide mixtures with 
electrospray mass spectrometry (EMS) [38] and disaccharides (KS, DS or CS) with high-performance 
liquid chromatography/turbo-ionspray tandem mass spectrometry tandem (LC-MS/MS) [39–41]. 
These methods are sensitive and accurate but its application is costly with some complicated 
procedures. Ramsay et al. developed a method for the derivatization and quantification of sulfated  
N-acetylhexosamine-containing mono- and di-saccharides from patient samples by electrospray 
ionization tandem mass spectrometry (ESI-MS/MS) [42,43]. Urine from most MPS types had 
significant increases in mono- and di-sulfated N-acetylhexosamines and mono-sulfated  
N-acetylhexosamine-uronic acid disaccharides. Analysis of plasma and DBS from patients with MPS 
indicated elevations of mono-sulfated N-acetylhexosamines but less than that seen in urine. This direct 
quantification of GAGs by mass spectrometry contained complex heterogeneous molecules with a 
variety of oligosaccharides. 
The major GAGs that accumulate in MPS patients are co-polymers that contain analogous repeating 
units (glucurono-, or iduronosulfo-N-acetyl-glucosamine or galactosamine). These polymers are 
sensitive to chemical and enzymatic degradation (methanolysis and hydrolysis) to produce simple 
disaccharide molecules containing the repeating subunits. The sulfate groups are quickly cleaved, and 
the remaining acidic polysaccharides are hydrolyzed or methanolyzed at certain glycosidic linkages 
and separate to stable disaccharides as the end products. In 2007, we developed a highly sensitive, 
specific, accurate, and low-cost strategy. Disaccharides derived from DS, HS, and KS are produced in 
blood and urine specimens by hydrolysis, and then all products analyzed by a single LC-MS/MS 
method [44–46]. Other groups have subsequently followed to analyze the disaccharides with similar 
methods [47,48]. A significant advantage of this approach is that multiple disaccharides are measured 
from a single sample, and that all types of MPS can be detected. Blood, urine, or other biological 
samples are purified by filtration and the GAGs are digested with chondroitinase B, heparitinase, and 
keratanase II to yield disaccharides of DS, HS, and KS. After digestion, the samples are loaded into  
the LC-MS/MS for quantitation, and the results are compared with control samples (Figure 2). The 
LC-MS/MS method for analysis of disaccharides not only shows sensitivity and specificity for 
detecting all subtypes of MPS but also can monitor therapeutic efficacy in MPS patients and animal 
models [27–45]. This method has an advantage of being both GAG-specific and quantitative. 
In 2011, Auray-Blais et al. described that methanolysis can be used to prepare disaccharides derived 
from HS and DS for LC-MS/MS analysis in urine of MPS patients [49,50]. Methanolysis has not yet 
been used to measure KS or blood samples. In 2012, Lawrence et al. showed that another new method 
with enzyme digestion can detect DS and HS by analysis of non-reducing ends of urinary GAGs by 
LC-MS/MS. Currently, this method does not provide a measure of non-reducing ends for KS [51]. 
Overall, establishment of methods to measure disaccharides makes it feasible to interpret individual 
GAG values, leading to feasible and accurate diagnosis, prognosis, and monitoring therapies for MPS.  
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Thus, several groups have contributed to methods that can assay disaccharides derived from CS, 
DS, HS, and KS in blood and/or urine samples by using LC-MS/MS for MPS. 
The LC-MS/MS method for disaccharides not only shows sensitivity and specificity for detecting 
all subtypes of MPS but defines the clinical severity and monitor therapeutic efficacy in MPS patients 
and animal models [46–48,52–57]. The main drawback of the LC step is that the process is time 
consuming, limiting its utility for the screening of large numbers of samples.  
Another unique method to measure the disaccharides of a specific GAG was developed by using 
RapidFire high-throughput mass spectrometry (HT-MS/MS). Samples are absorbed to a matrix to 
concentrate and desalt, and then eluted directly into the MS/MS without chromatographic separation. 
Each sample is processed in less than ten seconds, yielding much faster throughput than conventional 
LC-MS/MS based methods. A single 384 well plate can be read in ~45 min, indicating that this  
HT-MS/MS system can analyze over one million samples annually. The HT-MS/MS has been shown 
to provide sensitivity and specificity equivalent to standard MS/MS read-outs. The speed and 
efficiency of the HT-MS/MS can allow for experiments that would otherwise be deemed “untenable” 
under normal circumstances. The HT system has been validated as suitable for many drug  
discoveries [58–65] and ADME (Absorption, Distribution, Metabolism and Excretion) based 
applications [66]. The main drawback of this method is that disaccharides with identical molecular 
weights cannot be distinguished.  
Newborn screening (NBS) is recognized as an essential, preventive public health program for early 
identification of diseases that can improve long-term health outcomes. Tandem mass spectrometry 
(MS/MS) has evolved as a powerful tool to detect small compounds because the detection is based on 
the mass of the parent compound and a specific fragment(s) of the compound.  
4. MS/MS Method for Disaccharides  
4.1. Standards and Enzymes 
To digest “polymer” DS, HS, and KS to disaccharides, chondroitinase B, heparitinase, and 
keratanase II were provided from Seikagaku Co. (Tokyo, Japan). Heparitinase digests HS to yield the 
disaccharides ΔDiHS-0S, ΔDiHS-NS, and ΔDiHS-6S; chondroitinase B digests DS to yield ΔDi-4S; 
and keratanase II digests KS to yield Galβ1→4GlcNAc (6S) and Gal (6S) β1→4GlcNAc (6S)  
(mono- and di-sulfated KS disaccharides).  
Chondrosine was used as an internal standard (IS). The following standards were used to make 
standard curves of each specific disaccharide; ΔDi-6S (C6S) [2-acetamido-2-deoxy-4-O-(4-deoxy-a-L-
threo-hex-4-enopyranosyluronic acid)-6-O-sulfo-D-glucose], ΔDi-4S (DS) [2-acetamido-2-deoxy-4-O-
(4-deoxy-L-threo-hex-4-enopyranosyluronic acid)-4-O-sulfo-D-glucose], ΔDiHS-0S [2-acetamido-2-
deoxy-4-O-(4-deoxy-a-L-threo-hex-4-enopyranosyluronic acid)-D-glucose]; ΔDiHS-NS [2-deoxy-2-
sulfamino-4-O-(4-deoxy-a-L-threo-hex-4-enopyranosyluronic acid)-D-glucose]; ΔDiHS-6S (HS) [2-
acetamido-2-deoxy-4-O-(4-deoxy-a-L-threohex-4-enopyranosyluronic acid)-6-O-sulfo-D-glucose]; 
mono-sulfated KS-Galβ1-4GlcNAc(6S); di-sulfated KS - Gal(6S)β1-4GlcNAc(6S). All standards were 
provided by Seikagaku Corporation (Tokyo, Japan).  
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4.2. Sample Preparation 
Plasma/serum, urine, DBS, and standards were prepared as follows. Ten μL of each plasma/serum 
and urine sample and 90 μL of 50 mM Tris–hydrochloric acid buffer (pH 7.0) were placed in wells of 
AcroPrep™ Advance 96-Well Filter Plates that have Ultrafiltration Omega 10 K membrane filters 
(PALL corporation, NY, USA). The filter plates were placed on the receiver and centrifuged at 2000 g 
for 15 min to remove free disaccharides. The membrane plates were transferred to a fresh receiver 
plate. Standards were added to unused wells of the filter plate.  
Ten μL of IS solution (5 μg/mL), 20 μL of 50 mM Tris-HCl buffer, and 10 μL of chondroitinase B, 
heparitinase, and keratanase II, respectively (each 2 mU/10 μL of 50 mM Tris-HCl buffer), were added 
onto each filter. The plate was incubated at 37 °C for 5 h and centrifuged at 2000 g for 15 min. The 
processed samples were injected to LC-MS/MS or HT-MS/MS or stocked at −20 °C until use. 
4.3. LC-MS/MS 
We describe here the current LC-MS/MS method using enzyme digestion based on that originally 
developed by Oguma et al. [30,44,45]. We used two different LC-MS/MS instruments to quantify 
disaccharides; an HP1100 LC system (Agilent Technologies, Palo Alto, CA, USA) with API-4000 
(AB Sciex, Foster City, CA, USA) and a 1260 infinity LC system with 6460 Triple Quad (Agilent 
Technologies, Palo Alto, CA, USA) [30]. A Hypercarb column (2.0 mm i.d. 50 mm, 5 µm, Thermo 
Electron, USA) was used with both chromatographic systems. The mobile phase was a gradient elution 
from 0.025% ammonia to 90% acetonitrile in 0.025% ammonia. The mass spectrometer was operated in 
the negative ion detection mode with thermal gradient focusing electrospray ionization. Specific 
precursor ion and product ion were used to quantify each disaccharide [32,67,68]. A m/z 354.29 
precursor ion and m/z 193.1 product ion was used to detect the IS (chondrosine). The concentration of 
each disaccharide was calculated using Quantitative Analysis software.  
4.4. High-Throughput Tandem Mass Spectrometry (HT-MS/MS)  
Sample plates containing the disaccharides were centrifuged to collect all samples to the bottom of 
the plate, and applied to a RapidFire 200 (Agilent Technologies, Inc: Boston, MA, USA), followed by 
MS/MS in an API 4000 (ABSciex, Framingham, MA, USA) [30]. In the multiple reaction monitoring 
(MRM) mode, the mass spectrometer detected ions by monitoring the decay of specific precursor ion 
to the product ion for each disaccharide. The decay of the m/z 354.29 precursor ion to the m/z 193.1 
product ion was used for IS. The files from HT-MS/MS were merged to identify peaks and analyzed to 
determine the area under the curve (AUC). The levels of each disaccharide were measured and averaged. 
4.5. Disaccharide Determination Derived from GAGs 
4.5.1. LC-MS/MS 
Using purified preparations of ΔDiHS-0S, ΔDiHS-NS, and ΔDi-4S, we optimized MRMs for each 
individual sugar and obtained single peaks corresponding to the pure compound. All disaccharides are 
eluted in less than 3 min. The detection method for mono-sulfated Galβ1-4GlcNAc(6S) (KS1) also 
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detected some Gal(6S) β1-GlcNAc(6S) (KS2) at the same MRM but the two forms were clearly 
separated by chromatography. MRMs for ΔDiHS-0S and mono-sulfated KS patterns in MPS I-MPS 
VII are shown in Figure 2. 
4.5.2. HT-MS/MS  
The HT system does not have a chromatographic separation step but rather samples are first bound 
to solid phase matrix for desalting and concentration and then eluted directly into an MS/MS system. 
HT-MS/MS cannot distinguish disaccharides with identical molecular weights that give the same 
MRMs; however, this MS/MS can distinguish and quantify combinations of different disaccharides 
with a higher throughput (for example, see mono-sulfated KS in Figure 3). 
Figure 2. MRM of LC-MS/MS for plasma or serum samples in patients with MPS I-VII. 










HS (∆DiHS-0S) KS (Mono-sulfated-KS)
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Figure 3. Multiple reaction monitoring (MRM) of HT-MS/MS. (a) Multiple injections of 
mono-sulfated KS with a series of dilutions in duplicate shows seven gradient peaks per a 
set of dilutions (as well as other surrounding samples). (b) Multiple injections of chondosine 
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4.6. Analysis of Plasma and Serum Samples in MPS Patients by LC-MS/MS 
Each type of MPS has a different pattern of elevated GAG levels in the blood. We described the 
concentrations of DS-, HS-, and KS-derived disaccharides and their composition ratios in human 
control and MPS patients [44–46]. 
4.6.1. Keratan Sulfate 
Blood KS concentrations were found to vary with age as shown by ELISA (Figure 1). In healthy 
control newborns, blood KS concentration was under 2.0 μg/mL, and it rose, reaching a peak between 
0 and 2 years of age, and the concentrations stayed relatively constant until the individual reached  
15 years of age. After 15 years, blood KS concentrations decreased gradually and stabilized thereafter. 
When control subjects and MPS IVA patients in each age range were compared, the difference in KS 
levels between MPS IVA patients and the age-matched controls was greater at younger ages. It is 
noteworthy that KS level in patients with MPS IVA reduced with age and is almost normalized by the 
age of 15 years old. Blood KS levels in severe MPS IVA were higher than in the attenuated form. This 
finding indicates that KS level could be associated with clinical severity. The level of plasma KS was 
also compared between each type of MPS and age-matched controls. Plasma KS levels in 4 out of 31 
(12.9%) MPS I patients were more than 2SD above the mean of age-matched controls (Figure 4). 
Patients with MPS II had the highest mean KS in their blood among all types of MPS patients except 
MPS IV. Twenty-two out of 28 (78.6%) of MPS II patients had plasma KS values more than 2SD 
above the mean of age-matched controls (Figure 4). Plasma KS values in 5 of 19 (26.3%) MPS III 
patients, 3 of 6 (50%) MPS VI patients, and 1 of 6 MPS VII patients were more than 2SD above the 
mean of age-matched controls (Figure 4).  
The accumulation of undegraded KS leads to damage of cartilage cells, causing systemic skeletal 
dysplasia in patients with MPS IVA. KS, which contributes over 25% of the cartilage GAGs in adults, 
is one of the most important components in bone. When cartilage proteoglycans, such as KS, are not 
degraded properly, they are stored mainly in chondrocytes, where KS is synthesized. Pathological 
examinations of the bone and cartilage cells are useful for the diagnosis of MPS IVA; however, it is 
not practicable to obtain biopsy samples from every MPS IVA patient.  
Levels of elevation of KS detected by LC/MS/MS in plasma for MPS I, II, VI and VII are not as great 
as seen using ELISA methods and may reflect differences in the two assays or differences in the patient 
populations studied. The monoclonal antibody used for sandwich ELISA (Seikagaku, Tokyo, Japan) is 
specific for Galβ1(6S)→4GlcNAc(6S); i.e., both galactose and N-acetyl-glucosamine have to be 
sulfated [69,70]. Therefore, this analytical method does not provide quantification of total KS. 
Notably, total KS measured by LC/MS/MS was 10–100 times higher than measured by the sandwich 
ELISA method and the correlation between plasma KS measurements assayed by both methods for 
MPS IVA patients was weak. The ELISA method could also underestimate total and relative levels of 
KS due to poor quantitation of different degrees of KS polymerization. The LC/MS/MS method is also 
more sensitive than the ELISA method. While the ELISA method used in the study could not detect 
below 2.5 ng/mL of KS, LC/MS/MS could detect 0.2 ng/mL of KS. Consequently, in rodents that 
synthesize much less KS, blood levels are measurable by LC/MS/MS but not by ELISA. Although 
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ELISA methods do not require expensive equipment, LC/MS/MS methods are less expensive per sample 
and appear to be more sensitive and accurate. 
4.6.2. Dermatan Sulfate and Heparan Sulfate 
Plasma DS: All 4 MPS VI patients had a significant elevation of plasma DS, compared with the 
controls. MPS I (18/22, 81.8%), MPS II (26/27, 96.3%), MPS III (5/11, 45.5%), MPS VII (2/7, 28.6%) 
and ML II (3/7, 42.9%) patients also had a significant elevation of DS. These findings suggest that the 
measurement of DS levels by LC/MS/MS is applicable to the screening for MPS I, II, III and VI 
patients (Figure 4) [46]. 
Urine DS: All MPS VI patients (n = 3) had a marked elevation of urine DS, compared with the 
controls. All MPS I (n = 17) and MPS II (n = 19) patients also had a significant elevation. Two of three 
MPS III, two of five MPS IVA, and one of two MPS VII patients showed a significant elevation [46]. 
Thus, the secondary elevation of blood and/or urine DS was found in some of MPS III and IVA 
patients, although these patients should have normal levels of the enzymes needed to digest DS. 
Plasma HS: All MPS I, II, and III patients (60 out of 60 patients) had a significant elevation of 
plasma ΔDiHS-0S and ΔDiHS-NS, compared with the controls (Figure 4): The MPS III patient 
population included five IIIA patients, four IIIB patients and two IIIC patients. Two out of 6 MPS VII 
patients also had a significant elevation of HS [46]. 
Urine HS: Most MPS I, II, III and VII patients (36/39; 92.3%) had a significant elevation of urine 
HS (ΔDiHS-0S and ΔDiHS-NS), compared with age-matched controls. Two out of five MPS IVA and 
two out of three MPS VI patients also had a significant elevation [46]. 
Thus, the secondary elevation of blood and/or urine HS was observed in some of MPS IVA and VI 
patients (Figure 4), although these patients should have normal levels of the enzymes needed to digest HS. 
4.6.3. Composition of DS and HS in Blood 
The compositional ratio of ΔDiHS-0S, ΔDiHS-NS and ΔDiDS in total DS and HS derived from 
blood samples of MPS patients was compared. The ratio of the compositions was expected to be reflected 
by deficiency of each enzyme. For the normal control individuals, the mean ratio of ΔDiHS-0S, 
ΔDiHS-NS, and ΔDiDS in total DS and HS was 40.4%, 7.7%, and 51.9%, respectively. The proportion 
of ΔDiDS was significantly higher in MPS VI patients compared to that in normal controls  
(mean; 80.6% vs. 51.9%). The proportion of ΔDiHS-0S was significantly higher in MPS III and VII 
patients compared to that in normal controls (mean; 56.4% vs. 40.4%; 65.1% vs. 40.4%), suggesting 
that ΔDiHS-0S is dominant in MPS III and VII. The proportion of ΔDiHS-NS was also significantly 
higher in MPS III patients compared to that in normal controls (mean; 19.7% vs. 7.7%). Other types of 
MPS did not provide any significant difference in ratios of DS and HS. 
4.7. Analysis of Plasma and Serum Samples in MPS Patients by LC-MS/MS 
We analyzed plasma and serum samples for DiHS-NS and DiHS-0S in control subjects by both  
LC-MS/MS and HT-MS/MS. Initial analyses of ΔDiHS-NS and ΔDiHS-0S by LC-MS/MS and  
HT-MS/MS indicates that the results from each assay are comparable [30]. Furthermore, in a larger 
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studyHS levels were measured in plasma/serum from both control subjects and patients with MPS II, 
III, and IV [71]. 
Figure 4. Plasma KS, DS, and HS (ΔDiHS-0S and ΔDiHS-NS) levels by LC-MS/MS. 
 
The results showed (1) that there was a strong correlation of signals for disaccharides derived from 
ΔDiHS-NS and ΔDiHS-0S between conventional LC-MS/MS and HT-MS/MS, (2) that blood levels of 
ΔDiHS-NS, ΔDiHS-0S were significantly elevated in patients with MPS II and III, but not in patients 
with MPS IVA, (3) that the level of HS in patients with a severe form of MPS II was higher than that 
in an attenuated form, and (4) that reduction of blood HS level was observed in MPS II patients treated 
with enzyme replacement therapy or hematopoietic stem cell transplantation. 
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In conclusion, HT-MS/MS provides much higher throughput than LC-MS/MS-based methods with 
similar sensitivity and specificity in an HS assay, indicating that this method is feasible for diagnosis, 
monitoring, and screening of MPS. DS and KS levels are now under investigation. Once we have 
established all GAG assays by HT-MS/MS, we will be able to determine the relative advantages and 
disadvantages of LC-MS/MS and HT-MS/MS. 
4.8. Newborn MPS 
It is of great interest to know when GAGs begin to accumulate in tissues of the affected patients to 
apply GAG assays to newborn screening and to understand the correlation between GAG accumulation 
and the appearance of clinical signs and symptoms. Whether the elevation of GAGs is detectable in 
newborns with MPS was not known until recently. To evaluate if the LC-MS/MS method distinguishes 
MPS newborns from healthy control newborns, we measured DS and HS levels in DBS samples from 
six newborns with MPS (four MPS I, one MPS II, and one MPS VII) and compared them with control 
newborns. All six cases had significant elevations of DS and HS compared with the values of normal 
control newborns [67].  
Similarly, Ruijter et al. assayed DS and HS levels from newborn DBS of 11 MPS I, 1 MPS II, and 6 
MPS III patients, with phenotypes ranging from severe to relatively attenuated forms. The levels of DS 
and HS derived disaccharides in these DBS were compared with levels in DBS of newborn controls. 
The levels of DS and HS derived disaccharides were elevated in all newborn DBS of MPS I, II, and III 
patients when compared with controls [48]. 
Based on these results, we propose that DS and HS are a useful diagnostic and screening marker for 
MPS I, II, III, VI, and VII individuals. 
5. Secondary Elevation of KS  
There is a certain correlation between types of MPS and accumulated GAG(s) based upon the 
degradative enzyme affected (2). Elevation of KS level in blood and urine specimens was deemed as a 
hallmark of MPS IV since the deficient enzyme is directly engaged in catabolism of KS; however, 
MPS disorders other than MPS IV are also associated with elevated KS levels in blood and urine, in 
addition to the GAG accumulating due to the primary enzyme defect [28,31]. In particular, KS 
elevation in blood is more prominent than that in urine and is as high as the levels seen in patients with 
MPS IVA for many MPS sub-types. The elevation of urine KS in other types of MPS was not 
previously recognized due to the low sensitivity of conventional thin-layer chromatography (TLC) 
methods compared with the LC-MS/MS or ELISA methods described here. 
The majority of KS is synthesized in cartilage tissue, and the metabolized KS is secreted into the 
blood and excreted in urine. KS level in the normal population reaches a peak during the growth spurt 
and gradually decreases with age when the growth plate is being closed. MPS IV is caused by 
deficiency of the enzyme directly involved in KS degradation pathway, leading to accumulation of 
undegraded KS, mainly in cartilage. The resulting accumulation of undegraded KS damages the 
chondrocytes and their ECM. The structure of PGs and collagen in cartilage become abnormal, 
resulting in apoptosis of chondrocytes and the release of KS from the cells to the body fluids. The 
extent of elevated KS in blood and urine in patients with MPS IVA correlates positively with clinical 
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severity and its prognosis at a progressive stage [28,31,54]; however, KS level in patients decreases 
with age after 10 years of age, earlier than that in the normal population since the main synthetic site of 
KS in cartilage is destroyed and lost. Blood KS in MPS IVA is becomes similar to that seen in controls 
after patients become teenagers [28,31,54]. 
It is of importance to understand why KS is elevated in other types of MPS because the current 
understanding of the pathway of KS catabolism cannot account for this event.  
Several hypotheses have been proposed to explain the elevation of blood KS in patients with other 
types of MPS as follows (Figure 5):  
(1) The synthesis of KS is stimulated by storage of other GAGs. Accumulation of GAGs can 
induce pro-inflammatory factors such as IL-1β, 6, and 10 and TNF-α [14]. Accumulated GAGs 
and/or pro-inflammatory factors promote the synthesis of KS secondarily.  
(2) The elevation of KS is a secondary consequence caused by skeletal dysplasia. Accumulation of 
other GAGs could cause inflammation and thereby damage cartilage and its ECM leading to 
increased secretion of KS into the circulation. Degradation of PGs occurs early in joint damage. 
The fragments of PGs are released into the synovial fluid and subsequently the blood [72,73]. 
This hypothesis is supported by the fact that KS levels in patients with MPS I, II, and VI are 
more elevated, compared with that in MPS III that results in less marked skeletal dysplasia.  
KS elevation is more prominent in patients with a severe form of MPS II than in an attenuated 
phenotype [28,31]. An MPS VII mouse model has a severe skeletal abnormality and blood KS 
level is elevated more than other mouse models of MPS that have less marked skeletal 
abnormalities [74]. Elevated levels of KS were also seen in an MPS I mouse model but was 
limited in MPS IIIA and MPS IVA mice. These findings suggest that blood KS elevation is 
caused by release of KS from chondrocytes damaged due accumulation of other GAGs and 
subsequent inflammation. Paradoxically, in the MPS IVA mouse model a severe bone dysplasia 
is not seen and KS elevation in blood is limited despite the absence of functional GALNS 
enzyme. Thus, although KS would be expected to accumulate in cartilage of MPS IV mice, it is 
primarily the severity of bone dysplasia that correlates with levels of KS measured in blood. 
(3) GALNS activity is inhibited by HS that accumulates in patients with MPS. HS is known to 
directly inhibit GALNS enzyme activity in vitro. MPS IIIA, I and VII mice have increasing 
levels of HS and also increasing levels of serum KS, indicating a correlation between HS 
inhibition of GALNS and increased KS [74]. Patients with a severe form of MPS II have a high 
level of HS and a more prominent increase of KS at a young age. These findings support the 
hypothesis that inhibition of the GALNS enzyme by elevated HS causes a secondary elevation 
of KS levels in MPS I, II, III, and VII patients.  
(4) Polymer KS interacts and co-deposits with other accumulated GAGs. Co-deposition with other 
GAGs hinders the interaction between KS and enzymes that catabolize KS. Elevation of KS 
was less striking in urine than in blood for MPS other than MPS IV. The lower elevation of 
urine KS in patients with other forms of MPS could be explained by aggregation of KS with 
other GAGs or unknown factors in the bloodstream. The aggregates may be too large to be 
cleared into the urine. In this scenario, undegraded KS not filtered out by the kidney remain 
retained in the blood. 
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(5) Changes in the pattern of fucosylation, sialylation, and sulfation on KS secondary to other 
GAG accumulation makes KS resistant to degradation. KS derived from articular cartilage 
contains sialic acid and fucose. This hypothesis is supported by the fact that sialic acid residues, 
present as chain caps, and fucose residues inhibit degradation of KS molecules [75]. 
One or a combination of these factors may contribute to secondary elevation of KS. Further study 
will elucidate the mechanism. 
Most MPS patients have severe bone dysplasia. Therefore, elevated KS in the blood of other MPS 
patients could relate to underlying bone disease, especially cartilage tissues. Blood KS provides more 
specificity for the bone pathology of MPS disease than the originally stored substrates HS and/or DS. 
It would be useful to investigate the KS levels in the blood as a biomarker of other MPS. It is noteworthy to 
know whether KS concentrations are elevated in selected newborn babies with MPS from the viewpoint 
of early detection. Although MPS are progressive disorders that often take years to present clinically, 
there is considerable evidence from both in humans [76–78] and in animal models [79] that 
biochemical storage commences in the fetus.  
Figure 5. Hypotheses (H) of secondary elevation of blood KS in other MPS. H1; 
Accumulation of GAGs and pro-inflammatory factors induces KS synthesis. H2; GAG 
storage in chondrocyte leads to cell death and release of KS. H3; Accumulated HS leads to 
inhibition of GALNS activity. H4; Other GAGs co-deposited with KS masks the access of 
degradative enzymes for KS and undegraded KS is too large for filtration in kidney. H5; 


























We conclude that LC-MS/MS and HT-MS/MS provide a comparable sensitivity and accuracy for 
simultaneous measurement of three GAGs (DS, HS, and KS) and could be used for prognosis, 
diagnosis, monitoring, and screening. ELISA is another feasible and reproducible method although the 
variety of GAGs measurable is limited. Advantage of use of LC-MS/MS is that GAGs with the same 
molecular weight can be separated leading to accuracy and specificity of the differential diagnosis. 
HT-MS/MS provides a higher throughput and has the potential of being applied to screening for most 
inherited metabolic disorders, although this system cannot recognize the molecules with the same 
molecular weight separately. Secondary elevation of blood KS in other types of MPS in addition to 
MPS IV remains unsolved, but it should be valuable for diagnosis, monitoring, and screening for MPS 
related with skeletal dysplasia. Sulfation patterns of each specific GAG contribute to not only critical 
biological roles but also the differential diagnosis of MPS type. 
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